Advertisement

Topics

OSI Pharmaceuticals Company Profile

14:59 EDT 19th September 2017 | BioPortfolio

OSI Pharmaceuticals is committed to “shaping medicine and changing lives” by developing and commercializing high-quality and novel pharmaceutical products that extend life or improve the quality of life for patients with cancer, diabetes, and obesity. We specialize in the discovery and development of innovative molecular targeted therapies that address significant unmet medical needs, and strive to turn pioneering science into breakthrough therapies for patients suffering from life-threatening diseases. Our Oncology business is anchored by our flagship product, Tarceva® (erlotinib), a small molecule inhibitor of the epidermal growth factor receptor, or EGFR, that was first discovered and developed by OSI. Tarceva is the only EGFR inhibitor to have demonstrated the ability to improve overall survival in advanced non-small cell lung cancer and advanced pancreatic cancer. Behind Tarceva, we have an emerging oncology pipeline of molecular targeted therapies in clinical and late-stage pre-clinical development. Our R & D strengths include high-throughput screening, chemical libraries, medicinal and combinational chemistry and automated drug profiling technology platforms. Our diabetes and obesity R & D programs are conducted through Prosidion Limited, our U.K. subsidiary dedicated to the discovery and development of novel therapies for metabolic diseases, particularly type 2 diabetes and obesity. (OSI) Prosidion has an emerging diabetes and obesity clinical pipeline with several innovative drug candidates that have progressed into clinical development. OSI has a dedicated team of approximately 500 research and development, regulatory, sales, marketing, commercial, and business professionals. We are headquartered in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. Our Flagship Product Tarceva (erlotinib) is a small molecule human epidermal growth factor type 1/epidermal growth factor receptor (HER1/EGFR) inhibitor which is currently marketed for the treatment of non-small cell lung cancer and pancreatic cancer. Products and Pipeline A key to our long-term success resides in our ability to continue to fund our deep and innovative pipeline, both to enhance the Tarceva franchise and seed high-quality research programs in oncology, diabetes and obesity.

Location

41 Pinelawn Road
Melville,
NY
11747
United States of America

Contact

Phone: (631) 962-2000
Fax: (631) 752-3880
Email: investor_info@osip.com


News Articles [1258 Associated News Articles listed on BioPortfolio]

Deals this week: Pivot Pharmaceuticals, Innovation Pharmaceuticals, Portola Pharmaceuticals

Pivot Pharmaceuticals plans to acquire the worldwide rights to Altum Pharmaceuticals’ BiPhasix Transdermal drug delivery technology.

Inotek Pharmaceuticals announces merger deal with Rocket Pharmaceuticals

Inotek Pharmaceuticals announced that it has entered into a definitive merger agreement with US-based gene therapy company Rocket Pharmaceuticals.

Easton Pharmaceuticals Announces That Its Partner Windsor Pharmaceuticals Has Received Regulatory Approvals For Products VS-Sense and AL-Sense For Central America and The Caribbean

TORONTO, ON -- (Marketwired) -- 09/12/17 -- Easton Pharmaceuticals Inc. (OTC PINK: EAPH) and its JV partner BMV Medica SA de CV announces that its distributor Windsor Pharmaceuticals SA has receiv...

Ritter Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update

LOS ANGELES, CA -- (Marketwired) -- 08/07/17 -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a leading developer of novel therapeutic products that modu...

Earnings Preview: Valeant Pharmaceuticals

The week of May 8 is big for generic drug companies . Valeant Pharmaceuticals , Mylan , Endo International , and Teva Pharmaceuticals all report results this week.

Deals this week: Valeant Pharmaceuticals International, ImmunoPrecise Antibodies

Valeant Pharmaceuticals International has announced the sale of its subsidiary Dendreon Pharmaceuticals for $819.9m to Sanpower Group.

Easton Pharmaceuticals Announces That Its Partner Windsor Pharmaceuticals Has Received ...

TORONTO, ON--(Marketwired - Sep 12, 2017) -  Easton Pharmaceuticals Inc. ( OTC PINK : EAPH) and its JV partner BMV Medica SA de CV Read more...

CSE: 2017-0601 - Delist - Supreme Pharmaceuticals Inc. (SL)

TORONTO, ONTARIO -- (Marketwired) -- 06/01/17 -- The common shares of Supreme Pharmaceuticals Inc. will be delisted at the market close, June 5, 2017. Supreme Pharmaceuticals will continue to trad...

Drugs and Medications [270 Associated Drugs and Medications listed on BioPortfolio]

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash

Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

Antacid [Major Pharmaceuticals]

Major Pharmaceuticals Antacid Tablets Drug Facts

Eyewash station additive concentrate [Niagara Pharmaceuticals Inc.]

EYEWASH STATION ADDITIVE CONCENTRATE

PubMed Articles [158 Associated PubMed Articles listed on BioPortfolio]

Announcing the 2017 Pharmaceuticals Travel Award for Young Post-Doctoral Researchers.

Last year, for the first time in its history, our Journal was able to offer a travel grant of 800 CHF to a young researcher in the field of medicinal chemistry.

Suspended solids moderate the degradation and sorption of waste water-derived pharmaceuticals in estuarine waters.

This study focuses on the fate of pharmaceuticals discharged into an estuarine environment, particularly into the Turbidity Maximum Zone (TMZ). Batch experiments were set up to investigate the factors...

Chiral pharmaceuticals: A review on their environmental occurrence and fate processes.

More than 50% of pharmaceuticals in current use are chiral compounds. Enantiomers of the same pharmaceutical have identical physicochemical properties, but may exhibit differences in pharmacokinetics,...

Comparative study on pharmaceuticals adsorption in reclaimed water desalination concentrate using biochar: Impact of salts and organic matter.

The synergistic impact of salts and organic matter on adsorption of ibuprofen and sulfamethoxazole by three types of biochar and an activated carbon was investigated using reclaimed water reverse osmo...

Estimation of amount of selected pharmaceuticals sorbed onto digested sludge from wastewater treatment plant Bratislava-Petržalka.

Antibiotics and antidepressants are among the most successful drugs used for human therapy. Their concentration in influent on WWTP is relative high and there can be removed by biodegradation or sorpt...

Clinical Trials [198 Associated Clinical Trials listed on BioPortfolio]

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects Under Fasting Condition

- Objective: - To compare the rate and extent of absorption of Citalopram Hydrobromide Tablets 40 mg: Test Product: Citalopram Hydrobromide Tablets 40 mg manufactured b...

Bioequivalence Study of Hydrochlorothiazide 50mg Tablets Under Fasting Conditions

To compare the single-dose oral bioavailability of hydrochlorothiazide 50 mg tablet of Ohm Laboratories (A subsidiary of Ranbaxy pharmaceuticals USA) with hydrochlorothiazide 50 mg tablet ...

Companies [1277 Associated Companies listed on BioPortfolio]

Maelor Pharmaceuticals Ltd.

Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

Serenity Pharmaceuticals

Founded in 2007 and located in Milford, Pennsylvania, Serenity Pharmaceuticals is focused on developing products that address urinary conditions that impact the health and well-be...

Avanir Pharmaceuticals

AVANIR Pharmaceuticals, formerly LIDAK Pharmaceuticals, is a development stage company organized to discover, develop, and market novel therapeutic products to treat human diseases.

Future Pharmaceuticals

Future Pharmaceuticals magazine draws connections between industry leaders and pharmaceutical companies. Future Pharmaceuticals recommends next generation and groundbreaking strategies to ensure succe...

More Information about "OSI Pharmaceuticals" on BioPortfolio

We have published hundreds of OSI Pharmaceuticals news stories on BioPortfolio along with dozens of OSI Pharmaceuticals Clinical Trials and PubMed Articles about OSI Pharmaceuticals for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of OSI Pharmaceuticals Companies in our database. You can also find out about relevant OSI Pharmaceuticals Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Diabetes
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...


Corporate Database Quicklinks



Searches Linking to this Company Record